{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:37:46Z","timestamp":1774791466380,"version":"3.50.1"},"reference-count":38,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca, UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,1,4]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patient support programmes (PSPs) allow patients with chronic diseases to receive treatment and support at home. This study describes the Connect 360 PSP delivery and impact on patient-reported outcomes, satisfaction and adherence\/persistence among benralizumab-treated patients with severe eosinophilic asthma (SEA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A non-interventional retrospective cohort study using data collected during routine care in the Connect 360 PSP. All consenting enrollees (\u226518 years) were included in the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>746 patients formed the study cohort. Mean (SD) age was 53.7 (14.5) years on PSP entry; 38.3% were female (38.7% unknown). 79.6% of patients were experienced biological therapy users. Oral corticosteroid (OCS) use was reported in 48.4% of patients at baseline and 34.8% at 48 weeks. 8.2% of patients reported asthma hospitalisation in the previous 6 months at 24 weeks vs 3.0% at 48 weeks. Mean (SD) 6-item Asthma Control Questionnaire (ACQ-6) scores were 2.7 (1.5) at baseline vs 1.6 (1.3) at 48 weeks. Mean (SD) patient satisfaction scores remained high (4.5 of 5 (1.0) at baseline; 4.7 of 5 (0.6) at 48 weeks). 28.3% of patients were considered adherent at 24 weeks, increasing to 98.3% when supplemented with sales\/delivery data (sensitivity analysis). Discontinuation from PSP\/benralizumab was low at 24 (3.4%\/3.0%) and 48 (12.6%\/5.8%) weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Connect 360 PSP achieved high levels of satisfaction and persistence, with indications of positive outcomes including OCS use, hospitalisation and ACQ-6. The study was conducted during COVID-19, so it provides reassurance that patients with SEA receiving benralizumab may be supported safely and effectively at home.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2023-001734","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T12:40:10Z","timestamp":1706013610000},"page":"e001734","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and outcomes of patients enrolled in the Connect 360 benralizumab patient support programme in the UK: a retrospective cohort study"],"prefix":"10.1136","volume":"11","author":[{"given":"Tamsin","family":"Morris","sequence":"first","affiliation":[{"name":"Medical & Scientific Affairs, AstraZeneca UK, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wood","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Silvey","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Diomatari","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Lipworth","sequence":"additional","affiliation":[{"name":"Medical & Scientific Affairs, AstraZeneca UK, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8392-0728","authenticated-orcid":false,"given":"Shruti","family":"Menon","sequence":"additional","affiliation":[{"name":"Medical & Scientific Affairs, AstraZeneca UK, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"2025083112420806000_11.1.e001734.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025083112420806000_11.1.e001734.2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European respiratory society\/American Thoracic society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"2025083112420806000_11.1.e001734.3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.rmed.2016.12.017","article-title":"Severe and non-severe asthma in the community: A large electronic database analysis","volume":"123","author":"Varsano","year":"2017","journal-title":"Respir Med"},{"key":"2025083112420806000_11.1.e001734.4","unstructured":"Asthma UK . Slipping through the net: The reality facing patients with difficult and severe asthma. Available: https:\/\/www.asthma.org.uk\/6fc29048\/globalassets\/get-involved\/external-affairs-campaigns\/publications\/severe-asthma-report\/auk-severe-asthma-gh-final.pdf [accessed Jul 2022]."},{"key":"2025083112420806000_11.1.e001734.5","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025083112420806000_11.1.e001734.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2025083112420806000_11.1.e001734.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2025083112420806000_11.1.e001734.8","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2025083112420806000_11.1.e001734.9","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","article-title":"Benralizumab effectiveness in severe asthma is independent of previous biologic use","volume":"10","author":"Jackson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083112420806000_11.1.e001734.10","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of Mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083112420806000_11.1.e001734.11","unstructured":"Nucala Summary of Product Characteristics . Glaxosmithkline Https:\/\/Www.medicines.org.UK\/Emc\/Product\/1938#Gref2022. 2022. Available: https:\/\/www.medicines.org.uk\/emc\/product\/1938#gref"},{"key":"2025083112420806000_11.1.e001734.12","unstructured":"AstraZeneca . Cinqaero Summary of Product Characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/4370#gref [accessed Jul 2022]."},{"key":"2025083112420806000_11.1.e001734.13","unstructured":"AstraZeneca . Fasenra Summary of Product Characteristics. Available: https:\/\/www.medicines.org.uk\/emc\/product\/8918\/smpc#gref [accessed Jul 2022]."},{"key":"2025083112420806000_11.1.e001734.14","doi-asserted-by":"crossref","DOI":"10.4081\/mrm.2021.785","article-title":"Real world effectiveness of Benralizumab on respiratory function and asthma control","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip Respir Med"},{"key":"2025083112420806000_11.1.e001734.15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/JAA.S319572","article-title":"Real-world multicenter experience with Mepolizumab and Benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months","volume":"14","author":"Kayser","year":"2021","journal-title":"J Asthma Allergy"},{"key":"2025083112420806000_11.1.e001734.16","doi-asserted-by":"crossref","unstructured":"Kimura Y , Suzukawa M , Inoue N , et al . Real-world benefits of Biologics for asthma: exacerbation events and systemic corticosteroid use. World Allergy Organ J 2021;14. doi:10.1016\/j.waojou.2021.100600","DOI":"10.1016\/j.waojou.2021.100600"},{"key":"2025083112420806000_11.1.e001734.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-021-01785-z","article-title":"Real-world study in severe eosinophilic asthma patients refractory to anti-Il5 biological agents treated with Benralizumab in Spain (ORBE study)","volume":"21","author":"Mart\u00ednez-Morag\u00f3n","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2025083112420806000_11.1.e001734.18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JAA.S358738","article-title":"Reliability, satisfaction and effectiveness of Benralizumab home self-administration in patients with severe eosinophilic asthma in real-world practice: the auto-Benra study","volume":"15","author":"Garc\u00eda-Moguel","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2025083112420806000_11.1.e001734.19","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic Rhinosinusitis with nasal polyps: A real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083112420806000_11.1.e001734.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"2025083112420806000_11.1.e001734.21","unstructured":"National Institute for Health and Care Excellence (NICE) . COVID-19 rapid guideline: severe asthma. NICE guideline [NG166], Available: https:\/\/www.nice.org.uk\/guidance\/ng166 [accessed Jul 2022]."},{"key":"2025083112420806000_11.1.e001734.22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12325-018-0706-0","article-title":"Is patient support program participation associated with longer persistence and improved adherence among new users of Adalimumab? A retrospective cohort study","volume":"35","author":"Srulovici","year":"2018","journal-title":"Adv Ther"},{"key":"2025083112420806000_11.1.e001734.23","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1007\/s12325-021-01768-w","article-title":"Effect of a patient support program for idiopathic pulmonary fibrosis patients on medication persistence: A retrospective database analysis","volume":"38","author":"Near","year":"2021","journal-title":"Adv Ther"},{"key":"2025083112420806000_11.1.e001734.24","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2147\/PPA.S326498","article-title":"Assessing the beneficial impact of a patient support program in Secukinumab-treated patients with psoriasis in Italy","volume":"15","author":"Argenziano","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"2025083112420806000_11.1.e001734.25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/PPA.S343949","article-title":"Patient-support program in diabetes care during the COVID-19 pandemic: an Italian Multicentric experience","volume":"16","author":"Natalicchio","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"2025083112420806000_11.1.e001734.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2022.09.1955","article-title":"Diversity of patient support programs for severe asthma treated with biologic therapies \u2013 a systematic literature review","volume":"25","author":"Rabe","year":"2022","journal-title":"Value in Health"},{"key":"2025083112420806000_11.1.e001734.27","unstructured":"Impact of patient support programs on outcomes among patients with severe asthma treated with biologic therapies \u2013 a systematic literature review (accepted). In: British Thoracic Society Winter Meeting. London: QEII Centre, 2022."},{"key":"2025083112420806000_11.1.e001734.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.08.012"},{"key":"2025083112420806000_11.1.e001734.29","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2025083112420806000_11.1.e001734.30","unstructured":"StataCorp . Stata Statistical Software: Release 17. College Station TSL, 2021."},{"key":"2025083112420806000_11.1.e001734.31","doi-asserted-by":"crossref","unstructured":"d\u2019Ancona G , Stewart-Kelcher N , Bains S , et al . P105 Does asthma control change when patients transition to home administration of mepolizumab? British Thoracic Society Winter Meeting, Wednesday 17 to Friday 19 February 2021, Programme and Abstracts; February 2021:A144\u20135 doi:10.1136\/thorax-2020-BTSabstracts.250","DOI":"10.1136\/thorax-2020-BTSabstracts.250"},{"key":"2025083112420806000_11.1.e001734.32","doi-asserted-by":"crossref","unstructured":"d\u2019Ancona G , Bains S , Stewart-Kelcher N , et al . P104 Does asthma control change following transition to home benralizumab administration? British Thoracic Society Winter Meeting, Wednesday 17 to Friday 19 February 2021, Programme and Abstracts; February 2021:A144\u2013A44 doi:10.1136\/thorax-2020-BTSabstracts.249","DOI":"10.1136\/thorax-2020-BTSabstracts.249"},{"key":"2025083112420806000_11.1.e001734.33","unstructured":"D\u2019Ancona G , Stewart-Kelcher N , Bains S , et al . A multi-disciplinary teams\u2019 collaborative approach to transition Benralizumab dependent severe eosinophilic asthmatic patients to self-administration in response to the COVID-19 pandemic. 25th anniversary EAHP Congress - hospital Pharmacy 50 - the future of patient care. 2021."},{"key":"2025083112420806000_11.1.e001734.34","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-020-00728-y"},{"key":"2025083112420806000_11.1.e001734.35","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"Santomauro","year":"2021","journal-title":"The Lancet"},{"key":"2025083112420806000_11.1.e001734.36","first-page":"1086","article-title":"Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit","volume":"27","author":"Fendrick","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2025083112420806000_11.1.e001734.37","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11040960","article-title":"Severe asthma, Telemedicine, and self-administered therapy: listening first to the patient","volume":"11","author":"Guarnieri","year":"2022","journal-title":"J Clin Med"},{"key":"2025083112420806000_11.1.e001734.38","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jaip.2022.04.015","article-title":"Perceptions on home-administration of Biologics in the context of severe asthma: an international qualitative study","volume":"10","author":"Flokstra-de Blok","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-001734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:42:15Z","timestamp":1756669335000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-001734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,23]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjresp-2023-001734"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-001734","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}